Skip to content

Efficacy of flax seed oil in treating mild to moderate psoriasis vulgaris comparing with topical Bethamethasonel

Efficacy of flax seed oil in treating mild to moderate psoriasis vulgaris comparing with topical Bethamethasone: A randomized, double-blind, clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20191211045692N1
Enrollment
50
Registered
2020-04-01
Start date
2020-02-09
Completion date
Unknown
Last updated
2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PSORIASIS VULGARIS PLAQUE TYPE. Psoriasis vulgaris

Interventions

Intervention 1: - Intervention group: in this group, the certified flax seed oil, produced by Barij Essence Co., will be applied in the form of an ointment, delivered to the patient in the containers
the patients will be examined at the beginning of the study and the end of the first month by a physician, based on the questionnaires. Betamethasone ointment will be given to the patients in the same
it must be applied on lesions twice a day, and given massages. n the lesions and massaged.

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Type of psoriasis vulgaris disease with mild to moderate plaque type - Not to suffer underlying diseases disrupting the therapy, such as obesity, pregnancy, dialysis, AIDS, psychotic disorder, thyroid and parathyroid T d iseases Not to use medicines affecting psoriasis disease, such as Beta-blocker, lithium, anti-malaria, corticosteroids and systemic steroids, calcium channel blockers, interleukin Confirmation of clinical diagnosis by a dermatologist

Exclusion criteria

Exclusion criteria: - Suffering each of the abovementioned diseases or confirming the diagnosis of any disease, interfering with the treatment, and mentioned in the inclusion criteria, in any moment of the treatment cycle - Patient dissatisfaction with going on the treatment Any physical and chemical trauma and surgery, which inevitably makes the patient involved, and leads to the disease exacerbation

Design outcomes

Primary

MeasureTime frame
Erythem. Timepoint: At First and End of One Month. Method of measurement: PASI QUESTIONARE.;Scaling. Timepoint: At First and End of One Month. Method of measurement: PASI QUESTIONARE.;Induration. Timepoint: At First and End of One Month. Method of measurement: PASI QUESTIONARE.;Area. Timepoint: At First and End of One Month. Method of measurement: PASI QUESTIONARE.;PASI Score. Timepoint: At First and End of One Month. Method of measurement: PASI QUESTIONARE.;QUALITY OF LIFE. Timepoint: FIRST AND ONE MONTH LATER. Method of measurement: DLQ QUESTIONNARE.;SATICFACTION. Timepoint: FIRST AND ONE MONTH LATER. Method of measurement: SATISFACTION QUESTION.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarshad Mohammadian Rasanan

Iran University of Medical Sciences

fmr4077@yahoo.com+98 21 8837 6260

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026